PathoNostics is a molecular diagnostics company that develops and commercializes diagnostic assays for the infectious diseases market. The company was founded in 2011 as a result of the increasing demand for molecular diagnostic assays for invasive fungal and yeast infections. Our proprietary technology platform allows the development of new products and innovative molecular assays for the detection and identification of multiple pathogens and the screening of their resistance patterns. In addition to diagnostics on fungal & yeast infections, PathoNostics is currently involved in other projects including; veterinary health care, antibiotic/antifungal resistance and the development of other product-market combinations.

Our novel diagnostic assays will result in a significant faster diagnosis and specific species identification, leading to timely onset of targeted treatment. As a result, infection control and the avoidance of unnecessary medical treatment, side effects, and costs will be achieved. We are convinced that early diagnosis of fungal infections can greatly improve the success of treatment and prevent the spread of disease.